TECHNICAL GUIDANCE ON THE PHYSICOCHEMICAL AND FUNCTIONAL COMPARABILITY EXERCISE FOR TRASTUZUMAB BIOSIMILARS

Authors

  • AMMAR ALMAAYTAH Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan https://orcid.org/0000-0002-7804-3313

DOI:

https://doi.org/10.22159/ijap.2022v14i4.44963

Keywords:

Trastuzumab;, Biosimilars;, Similarity;, Biological comparability;, Guidance

Abstract

The introduction of monoclonal antibodies (mAbs) into the field of oncology has revolutionized the treatment options available to clinicians for the treatment of several malignancies. Unlike their classical small molecule drug counterparts, mAbs are large complex biological molecules that are generated using recombinant engineering and produced through the use of living systems. The high complexity of these agents combined with the complexity of their manufacturing process poses significant challenges for the pharmaceutical industry in producing exact copies of the originator molecules. With several mAbs losing their patency in recent years, several pharmaceutical manufacturers are pursuing the development of mAb copies or what is known as biosimilars as generic copies to the originator mAbs. Developing a mAb biosimilar requires that the manufacturer performs an extensive comparability exercise between the originator mAb and its biosimilar to provide evidence that the biological copy is similar to the originator in regards to physicochemical and functional properties, non-clinical pharmacodynamics and immunogenicity, and finally clinical trials to ensure the safety and efficacy of the biological molecule. The inability to perform a high-quality similarity exercise could generate inferior biological copies or what is known as intended copies. Trastuzumab is a humanized mAb that was designed to target HER 2 receptors which are highly expressed in a variety of tumors including 25-30% of invasive breast carcinomas. The aim of this review is to provide technical guidance regarding the physicochemical and functional similarity exercise for pharmaceutical personnel working in the research and development of Trastuzumab biosimilars in addition to regulatory officers worldwide reviewing biosimilars dossiers within public health authorities. This data will provide valuable information in detailing the main quality parameters needed to demonstrate the analytical similarity of any Trastuzumab biosimilar to its reference product.

Downloads

Download data is not yet available.

References

Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Critical Reviews in Oncology/Hematology. 2005;54(1):11–29.

Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: Clinical Studies for Trastuzumab Biosimilars. British Journal of Cancer. 2019;121(3):199–210.

Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA: A Cancer Journal for Clinicians. 2013;63(4):249–79.

Kumar A. Comprehensive review on etiopathogenesis, treatment and emerging therapies of breast cancer. Asian Journal of Pharmaceutical and Clinical Research. 2021;:20–33.

Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/Neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews. 2008;34(6):539–57.

Oostra D, Macrae E. Role of Trastuzumab Emtansine in the treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy. 2014;:103.

Kumar NM, Sivadas A, R L. Trastuzumab-induced respiratory distress: A case report. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(10):1.

Zhou BP, Liao Y, Xia W, Spohn B, Lee M-H, Hung M-C. Cytoplasmic localization of P21CIP1/WAF1 by Akt-induced phosphorylation in HER-2/Neu-overexpressing cells. Nature Cell Biology. 2001;3(3):245–52.

Maadi H, Nami B, Tong J, Li G, Wang Z. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer. 2018;18(1).

Arteaga C, Moulder S, Yakes F. Her (erbb) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology. 2002;29(3):4–10.

Browne B, O'Brien N, Duffy M, Crown J, O'Donovan N. Her-2 signaling and inhibition in breast cancer. Current Cancer Drug Targets. 2009;9(3):419–38.

Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. New England Journal of Medicine. 2007;357(1):39–51.

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by her2 status and trastuzumab treatment: An institutional-based review. Journal of Clinical Oncology. 2010;28(1):92–8.

Dranitsaris G, Amir E, Dorward K. Biosimilars of Biological Drug Therapies. Drugs. 2011;71(12):1527–36.

Declerck PJ. Biologicals and Biosimilars: A review of the science and its implications. Generics and Biosimilars Initiative Journal. 2012;1(1):13–6.

Temel DB, Landsman P, Brader ML. Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies. Methods in Enzymology. 2016;:359–89.

Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nature Biotechnology. 2016;34(4):393–400.

Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology Research & Perspectives. 2019;7(6).

Ahuja N, Rajawat J. Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. International Journal of Applied Pharmaceutics. 2021;:31–40.

Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. mAbs. 2011;3(2):107–10.

Chow S-C, Wang J, Endrenyi L, Lachenbruch PA. Scientific considerations for assessing biosimilar products. Statistics in Medicine. 2012;32(3):370–81.

Declerck PJ. Biosimilar monoclonal antibodies: A science-based Regulatory Challenge. Expert Opinion on Biological Therapy. 2013;13(2):153–6.

Cornes P, Aapro M. The impact of biosimilars in supportive care in cancer. European Oncology & Haematology. 2018;14(1):20.

Castaneda-Hernandez G, Gonzalez-Ramirez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: What the clinician should know. RMD Open. 2015;1(1).

Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatology International. 2016;36(5):613–25.

Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A multidisciplinary perspective. Clinical Therapeutics. 2016;38(5):1238–49.

Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: Regulatory considerations and building confidence for the Healthcare Community. BioDrugs. 2017;31(3):175–87.

López-Morales CA, Miranda-Hernández MP, Juárez-Bayardo LC, Ramírez-Ibáñez ND, Romero-Díaz AJ, Piña-Lara N, et al. Physicochemical and biological characterization of a biosimilar trastuzumab. BioMed Research International. 2015;2015:1–10.

Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe. mAbs. 2013;5(5):621–3.

Flad T, Chumsae C. Primary structure and peptide mapping. Monoclonal Antibodies. 2021;:93–119.

Háda V, Bagdi A, Bihari Z, Timári SB, Fizil Á, Szántay C. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of Protein biotherapeutics: A viewpoint from the biosimilar industry. Journal of Pharmaceutical and Biomedical Analysis. 2018;161:214–38.

Li W, Kerwin JL, Schiel J, Formolo T, Davis D, Mahan A, et al. Structural elucidation of post-translational modifications in monoclonal antibodies. ACS Symposium Series. 2015;:119–83.

Bennett KL, Smith SV, Truscott RJW, Sheil MM. Monitoring papain digestion of a monoclonal antibody by electrospray ionization mass spectrometry. Analytical Biochemistry. 1997;245(1):17–27.

Wang S, Ionescu R, Peekhaus N, Leung J-yu, Ha S, Vlasak J. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. Journal of Chromatography A. 2010;1217(42):6496–502.

Gokarn Y, Agarwal S, Arthur K, Bepperling A, Day ES, Filoti D, et al. Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies. ACS Symposium Series. 2015;:285–327.

Lin JC, Glover ZK, Sreedhara A. Assessing the utility of circular dichroism and FTIR spectroscopy in monoclonal-antibody comparability studies. Journal of Pharmaceutical Sciences. 2015;104(12):4459–66.

Wen J, Batabyal D, Knutson N, Lord H, Wikström M. A comparison between emerging and current biophysical methods for the assessment of higher-order structure of Biopharmaceuticals. Journal of Pharmaceutical Sciences. 2020;109(1):247–53.

Garidel P, Hegyi M, Bassarab S, Weichel M. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnology Journal. 2008;3(9-10):1201–11.

Molina P, Schick AJ, Welch L, Niedringhaus T, Hierro Gdel, Deperalta G, et al. Using differential scanning calorimetry for the development of non-reduced capillary electrophoresis sodium dodecyl sulfate methods for monoclonal antibodies. Analytical Biochemistry. 2020;609:113948.

Vulto AG, Jaquez OA. The process defines the product: What really matters in biosimilar design and production? Rheumatology. 2017;56(suppl_4):iv14–iv29.

Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Critical Reviews in Biotechnology. 2021;41(2):300–15.

Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals. 2011;39(2):100–9.

Sanchez-De Melo I, Grassi P, Ochoa F, Bolivar J, García-Cózar FJ, Durán-Ruiz MC. N-glycosylation profile analysis of trastuzumab biosimilar candidates by normal phase liquid chromatography and MALDI-TOF MS approaches. Journal of Proteomics. 2015;127:225–33.

Kaji H, Yamauchi Y, Takahashi N, Isobe T. Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site–specific stable isotope tagging. Nature Protocols. 2006;1(6):3019–27.

Duivelshof BL, Jiskoot W, Beck A, Veuthey J-L, Guillarme D, D’Atri V. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications. Analytica Chimica Acta. 2019;1089:1–18.

Gupta S, Jiskoot W, Schöneich C, Rathore AS. Oxidation and deamidation of monoclonal antibody products: Potential impact on stability, biological activity, and efficacy. Journal of Pharmaceutical Sciences. 2022;111(4):903–18.

Trivedi M, Laurence J, Siahaan T. The role of thiols and disulfides on protein stability. Current Protein & Peptide Science. 2009;10(6):614–25.

Beck A, Liu H. Macro- and micro-heterogeneity of natural and recombinant IGG antibodies. Antibodies. 2019;8(1):18.

Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Current Pharmaceutical Biotechnology. 2008;9(6):468–81.

Zhao Y-Y, Wang N, Liu W-H, Tao W-J, Liu L-L, Shen Z-D. Charge variants of an avastin biosimilar isolation, characterization, in vitro properties and pharmacokinetics in rat. PLOS ONE. 2016;11(3).

Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IGG1. mAbs. 2010;2(6):613–24.

Ratih R, Asmari M, Abdel-Megied AM, Elbarbry F, El Deeb S. Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchemical Journal. 2021;165:106143.

Bedard P, de Azambuja E, Cardoso F. Beyond trastuzumab: Overcoming resistance to targeted her-2 therapy in breast cancer. Current Cancer Drug Targets. 2009;9(2):148–62.

Jeong SA, Choi JM, Park JM, Lee JY, Lee SJ, Lee SY, et al. Mechanism of action of the trastuzumab biosimilar CT-P6. Expert Opinion on Biological Therapy. 2018;19(10):1085–95.

Jassem S, Wang W, Sweet H, Manoukian R, Chow V, Kanakaraj P, et al. Functional and nonclinical similarity of ABP 980, a biosimilar of Trastuzumab. Pharmaceutical Research. 2019;36(12).

Joshi S, Rathore AS. Assessment of structural and functional comparability of biosimilar products: Trastuzumab as a case study. BioDrugs. 2020;34(2):209–23.

Published

28-05-2022

How to Cite

ALMAAYTAH, A. (2022). TECHNICAL GUIDANCE ON THE PHYSICOCHEMICAL AND FUNCTIONAL COMPARABILITY EXERCISE FOR TRASTUZUMAB BIOSIMILARS. International Journal of Applied Pharmaceutics, 14(4). https://doi.org/10.22159/ijap.2022v14i4.44963

Issue

Section

Review Article(s)